Tecemotide in unresectable stage III non-small cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses.
Authors
Mitchell, PThatcher, Nick
Socinski, M
Wasilewska-Tesluk, E
Horwood, K
Szczesna, A
Martín, C
Ragulin, Y
Zukin, M
Helwig, C
Falk, M
Butts, C
Shepherd, F
Affiliation
Olivia Newton-John Cancer and Wellness Centre, Austin Hospital, Melbourne, VIC, AustraliaIssue Date
2015-02-26
Metadata
Show full item recordAbstract
Tecemotide is a MUC1-antigen-specific cancer immunotherapy. The phase III START study did not meet its primary endpoint but reported notable survival benefit with tecemotide versus placebo in an exploratory analysis of the predefined patient subgroup treated with concurrent chemoradiotherapy. Here, we attempted to gain further insight into the effects of tecemotide in START.Citation
Tecemotide in unresectable stage III non-small cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses. 2015: Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdv104PubMed ID
25722382Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdv104
Scopus Count
Collections
Related articles
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
- Authors: Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA, START trial team.
- Issue date: 2014 Jan
- Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
- Authors: Katakami N, Hida T, Nokihara H, Imamura F, Sakai H, Atagi S, Nishio M, Kashii T, Satouchi M, Helwig C, Watanabe M, Tamura T
- Issue date: 2017 Mar
- Tecemotide: an antigen-specific cancer immunotherapy.
- Authors: Wurz GT, Kao CJ, Wolf M, DeGregorio MW
- Issue date: 2014
- TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
- Authors: Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM
- Issue date: 2016 Feb
- Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
- Authors: Rossmann E, Österborg A, Löfvenberg E, Choudhury A, Forssmann U, von Heydebreck A, Schröder A, Mellstedt H
- Issue date: 2014